公开(公告)号：US20230190657A1

公开(公告)日：2023-06-22

申请号：US17926040

申请日：2021-05-21

Applicant: TRUSTEES OF BOSTON UNIVERSITY ,  BETH ISRAEL DEACONESS MEDICAL CENTER

Inventor： Mark W. Grinstaff ,  William Blessing ,  Amanda Williamson ,  Jack Kirsch ,  Katherine Cook ,  Ara Nazarian ,  Edward K. Rodriguez

IPC: A61K9/16 ,  A61K38/22 ,  A61K9/19 ,  A61K9/00 ,  A61P19/02 ,  A61P11/00

CPC classification number: A61K9/1647 ,  A61K9/008 ,  A61K9/19 ,  A61K9/1635 ,  A61K38/2221 ,  A61P11/00 ,  A61P19/02

Abstract: The present invention provides compositions and methods for the treatment of diseases and disorders. In some embodiments the compositions and methods involve administration of a microparticle, or composition thereof that includes an antifibrotic.

公开(公告)号：US11674125B2

公开(公告)日：2023-06-13

申请号：US16954814

申请日：2018-12-17

Applicant: THE GENERAL HOSPITAL CORPORATION

Inventor： Robert M. Anthony ,  Maya Kitaoka

IPC: C12N9/10 ,  A61P37/06 ,  A61P19/02 ,  A61P13/12 ,  A61K38/00

CPC classification number: C12N9/1081 ,  A61P13/12 ,  A61P19/02 ,  A61P37/06 ,  C12N9/1051 ,  C12Y204/01038 ,  C12Y204/99001 ,  A61K38/00 ,  C07K2319/30

Abstract: This disclosure relates to glycoengineering, and methods of utilizing glycoengineering for various therapeutic purposes.

公开(公告)号：US11672815B2

公开(公告)日：2023-06-13

申请号：US17165627

申请日：2021-02-02

Applicant: CUPIONE CO., LTD.

Inventor： Siyoung Yang ,  Jimin Jeon ,  Li-Jung Kang ,  Chanmi Cho

IPC: A61K31/702 ,  A23L33/125 ,  A61P17/00 ,  A61P19/02

CPC classification number: A61K31/702 ,  A23L33/125 ,  A61P17/00 ,  A61P19/02 ,  A23V2002/00 ,  A23V2002/00 ,  A23V2200/318 ,  A23V2250/612

Abstract: Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.

公开(公告)号：US20230174939A1

公开(公告)日：2023-06-08

申请号：US17985365

申请日：2022-11-11

Applicant: Stellular Bio, Inc.

Inventor： Dean Falb

IPC: C12N5/078 ,  A61P17/02 ,  A61P19/02 ,  A61P17/14 ,  C07K14/475

CPC classification number: C12N5/0644 ,  A61P17/02 ,  A61P19/02 ,  A61P17/14 ,  C07K14/475 ,  C12N2506/03

Abstract: Described herein are methods for treating, repairing or ameliorating diseases, disorders, or injuries related to dry eye, osteoarthritis, tendon, ligament, bone repair, wound healing or wound-healing related disorders, alopecia or in skin rejuvenation or regeneration with platelet-like-cells or variants thereof (PLCs) or derivatives thereof or lysates thereof or the platelet rich plasma (PRP) derived therefrom. Also, described herein are methods for generating platelet rich plasma (PRP) from the PLCs or derivatives thereof or lysates thereof.

公开(公告)号：US20230174682A1

公开(公告)日：2023-06-08

申请号：US18103132

申请日：2023-01-30

Applicant: KiOmed Pharma

Inventor： Mickaël Chausson ,  Pierre Douette ,  Sandrine Emilia Gautier ,  Philippe Vaesen ,  Houtaï Choumane ,  Guillermo Rocasalbas

IPC: C08B37/08 ,  A61P19/02 ,  A61K9/00 ,  A61K31/722 ,  A61L27/20

CPC classification number: C08B37/003 ,  A61P19/02 ,  A61K9/0019 ,  A61K31/722 ,  A61L27/20 ,  A61L2400/06 ,  A61L2430/06

Abstract: The present invention relates to a carboxyalkyl chitosan, compositions comprising same, a process for manufacturing same, and various applications thereof, in particular in the field of therapy, rheumatology, ophthalmology, esthetic medicine, plastic surgery, internal surgery, dermatology or cosmetics.

公开(公告)号：US20230174657A1

公开(公告)日：2023-06-08

申请号：US17926018

申请日：2021-05-25

Applicant: SANOFI BIOTECHNOLOGY

Inventor： Inka ALBRECHT ,  Eugen FEIST ,  Peer-Malte ARIES ,  Silke ZINE ,  Harald BURKHARDT ,  Hans-Peter TONEY

IPC: C07K16/28 ,  A61P19/02 ,  A61K39/395 ,  A61K31/519 ,  A61P29/00

CPC classification number: C07K16/2866 ,  A61P19/02 ,  A61K39/3955 ,  A61K31/519 ,  A61P29/00 ,  A61K2039/505

Abstract: The present technology provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R).

公开(公告)号：US11667727B2

公开(公告)日：2023-06-06

申请号：US16767571

申请日：2018-11-09

Applicant: KiOmed Pharma

Inventor： Mickaël Chausson ,  Pierre Douette ,  Sandrine Emilia Gautier ,  Philippe Vaesen ,  Houtaï Choumane ,  Guillermo Rocasalbas

IPC: A61P19/02 ,  A61K31/722 ,  C08B37/08 ,  A61K9/00 ,  A61L27/20

CPC classification number: C08B37/003 ,  A61K9/0019 ,  A61K31/722 ,  A61L27/20 ,  A61P19/02 ,  A61L2400/06 ,  A61L2430/06

Abstract: The present invention relates to a carboxyalkyl chitosan, compositions comprising same, a process for manufacturing same, and various applications thereof, in particular in the field of therapy, rheumatology, ophthalmology, esthetic medicine, plastic surgery, internal surgery, dermatology or cosmetics.

公开(公告)号：US11667720B1

公开(公告)日：2023-06-06

申请号：US18176957

申请日：2023-03-01

Applicant: Hoffmann-La Roche Inc. ,  Chugai Seiyaku Kabushiki Kaisha

Inventor： Xiaoping Zhang ,  Kimio Terao

IPC: A61K39/395 ,  C07K16/28 ,  A61K38/47 ,  A61K9/00 ,  A61K31/573 ,  A61K39/00 ,  A61P37/06 ,  A61P19/02 ,  A61P29/00

CPC classification number: C07K16/2866 ,  A61K9/0019 ,  A61K31/573 ,  A61K38/47 ,  A61K39/3955 ,  A61K39/39533 ,  C12Y302/01035 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2300/00 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/94

Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.

公开(公告)号：US11649283B2

公开(公告)日：2023-05-16

申请号：US15488351

申请日：2017-04-14

Applicant: ImmuNext, Inc ,  Janssen Pharmaceuticals, Inc.

Inventor： Michael Molloy ,  Jay Rothstein ,  Dov Pechenick ,  Linda Snyder ,  Gordon Powers

IPC: C07K16/28 ,  A61K39/395 ,  A61P17/06 ,  A61P1/16 ,  A61P37/06 ,  A61P19/02 ,  A61P13/12 ,  A61P1/00 ,  A61K45/06 ,  A61K38/17 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K38/17 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61P1/00 ,  A61P1/16 ,  A61P13/12 ,  A61P17/06 ,  A61P19/02 ,  A61P37/06 ,  C07K16/2827 ,  C07K16/2896 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

公开(公告)号：US11648286B2

公开(公告)日：2023-05-16

申请号：US16645957

申请日：2018-09-14

Applicant: KINE SCIENCES CO., LTD.

Inventor： Dae Ho Cho ,  Kyung Eun Kim ,  Myun Soo Kim ,  Sun Young Park ,  Hee Young Jung

IPC: A61K38/06 ,  A61P37/00 ,  A61P19/02 ,  A61K38/08 ,  A61K38/10

CPC classification number: A61K38/06 ,  A61K38/08 ,  A61K38/10 ,  A61P19/02 ,  A61P37/00

Abstract: The present invention relates to use of peptides as a therapeutic agent, wherein it has been confirmed that the peptides of the present invention significantly inhibit the activity of T cells and the differentiation of T helper 17 cells (Th17 cells), which are associated with autoimmune disease, reduce the secretion of inflammatory cytokine IL-6, and have remarkable effects of treating and improving arthritis in an animal model of arthritis. Therefore, the peptides may be used as an active ingredient in therapeutic agents for various autoimmune diseases such as bone disease, inflammatory disease or rheumatoid arthritis.